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A protease inhibitor unsticks cells
 
AI-1 is unique among protease inhibitors because it binds to 
the matrix protein vitronectin (VN). PAI-1 binding blocks 
VN’s binding site for the cell surface receptor uPAR and for integrin 
family members. Czekay et al. (page 781) now show that PAI-1
is also able to detach cells through a less direct approach.
Unlike the direct comp-
etition method, PAI-1 also 
disrupted integrin-mediated 
adhesion without ever 
contacting VN. Instead, 
PAI-1 bound to another 
uPAR ligand, the protease 
uPA. Binding of uPA to 
uPAR causes integrin 
recruitment into complexes 
with uPA and uPAR. PAI-1 
disrupted adhesion by 
inactivating these complexes 
and triggering their endo-
cytosis. Endocytosis required 
the low density lipoprotein receptor-related protein, but how PAI-1 
triggers integrin inactivation has yet to be determined.
Integrins interact with other matrix molecules in addition to VN. 
So far, the authors have shown that PAI-1 also detaches cells from 
fibronectin and collagen, again by promoting integrin endocytosis. 
In each case, cells expressing high levels of uPAR were more 
susceptible to PAI-1–induced detachment, because more of their 
surface integrins were complexed with uPAR. This association could 
explain why a high level of PAI-1 indicates a poor prognosis for many 
metastatic cancers—unusual for a protease inhibitor, since proteases 
normally promote cell invasion. 
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PAI-1 (yellow) causes integrins (blue) 
associated with uPAR (red circles) to 
be recycled.
 
PDE5 says NO to cGMP
 
short burst of nitric oxide (NO) is remembered by a 
phosphodiesterase long after NO levels decline, according 
to results on page 719 by Mullershausen et al. The memory
of this enzyme, PDE5, may be responsible for the tolerance 
that patients develop to nitrovasodilators like nitroglycerin.
Nitrovasodilators are NO-
releasing compounds that are 
used to treat coronary heart 
disease. NO increases cellular 
cGMP levels, which lowers blood 
pressure by both relaxing blood 
vessels and inhibiting platelet 
aggregation. But platelets rapidly 
decrease NO-induced cGMP 
and thus become desensitized 
to later NO exposure. Circum-
stantial evidence suggests that the cGMP is degraded upon 
phosphorylation of the phosphodiesterase PDE5 by a cGMP-
dependent kinase. The new article describes a more direct 
route of cGMP self-limitation.
As expected, NO-induced PDE5 phosphorylation required 
cGMP increases and the cGMP-dependent kinase cGKI. Yet 
phosphorylation was not necessary for PDE5 activation by 
cGMP, as shown using cGKI-deficient mice. Instead, cGMP 
was sufficient to activate PDE5. Others recently showed that 
cGMP binds to and activates PDE5. This interaction probably 
provides the direct mechanism for NO-induced PDE5 
activation. Low concentrations of cGMP, however, stimulated 
only phosphorylated PDE5, suggesting that the modification 
may increase cGMP affinity.
A small, transient NO stimulus dampened subsequent 
cGMP production in response to NO 
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h later, at which 
time PDE5 was still active. Inhibition of this active PDE5 may 
be necessary to achieve lasting nitrovasodilator therapy.
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PDE5 activation by cGMP 
does not require, but is 
enhanced by, phosphory-
lation (open circles).
 
Ran sticks a GEF to chromatin
 
radients of the small GTPase Ran are important 
throughout the cell cycle. High nuclear RanGTP 
concentrations in interphase cells regulate nuclear 
transport. During mitosis, chromosome-localized 
RanGTP releases spindle assembly factors from 
sequestration by importins. On page 635, Li et al. 
demonstrate that RanGTP accumulates at chromo-
somes because the complex of Ran and its guanine 
nucleotide exchange factor (GEF) binds strongly to 
chromatin.
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GTP-bound Ran is produced by the GEF RCC1, which binds 
only weakly to histones. Using a GFP-tagged version, the 
authors show that RCC1 is highly mobile and exchanges rapidly 
between free and chromatin-bound states. As RCC1 has strong 
GEF activity in the presence or absence of chromatin, the 
authors were interested in determining how RanGTP production 
is limited to chromosomes. They found that Ran-bound RCC1 
had a stronger chromosome association. Locking RCC1 to 
Ran, using a mutant 
version of Ran, 
immobilized RCC1 
on chromosomes. 
Ran also enhanced 
RCC1 binding to 
chromatin in vitro. 
Only nucleotide 
exchange, which 
displaces RCC1 
Ran-bound RCC1 (bottom) is less mobile (circle, left 
to right) at chromosomes than is unbound RCC1 (top).
 
from Ran, released the GEF and RanGTP from chromosomes.
The increased affinity of the complex for chromosomes can 
be explained by its binding geometry. RCC1 binds histones 
H2A and H2B, whereas Ran binds weakly to histones H3 
and H4. The complex is therefore well suited to bind to 
nucleosome octamers. Thus, exploiting the geometry of 
nucleosomes is a simple way to couple GTP exchange to 
chromatin-bound Ran.
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